#image_title

Eternal Material Technology: Driving Digital Transformation with iLabPower and AI Integration

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Bawei Biotechnology Transforms R&D Efficiency with iLabPower Digital Solutions

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Zhuhai United Laboratories: Driving Innovation through Comprehensive Digital R&D Transformation

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Digital Transformation at Yichang HEC: Elevating CMC R&D through Comprehensive Digital Solutions

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Transforming R&D Efficiency: How Shanghai Xihua Pharmaceutical Leveraged Digital Solutions for Seamless Project and Laboratory Management

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

saas-concept-collage

90% Performance Improvement! Electronic Lab Notebook (ELN) Achieves Historic Speed-Up

The Electronic Lab Notebook (ELN) has long been an indispensable tool for modern labs, but traditional versions often suffer from slow page responsiveness, hampering work efficiency. To address this, we have launched iLabPower ELN 4.0, a cloud-native solution designed for maximum speed and scalability.

#image_title

 

Built with containerized deployment and powered by Kubernetes for task scheduling, ELN 4.0 is faster and more stable than ever, achieving a 90% performance boost. The average response time for key pages, such as the test task page, has been reduced to just 0.136 seconds. For management and approval pages, response times now average below 0.35 seconds, drastically improving workflow and reducing bottlenecks in experiment management.

 

This enhanced version of ELN breaks through performance barriers, ensuring faster data recording, streamlined experimental processes, and a much smoother user experience. The real-time responsiveness allows researchers to focus more on science and less on waiting for pages to load.

 

Key benefits include:

  • Faster page response times: Average load time for key pages is now 0.2 seconds.
  • Increased efficiency: Tasks like experiment approval and sample management are significantly sped up.
  • Scalability: ELN 4.0 can automatically scale to meet demand, ensuring availability during peak usage times.

 

While ELN 4.0 has brought unprecedented improvements in speed and reliability, our commitment to continuous optimization remains, ensuring labs have the tools they need to support the ever-evolving demands of scientific research.